ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC 11.04.2024
About Gravity Analytica
Recent News
- 01.14.2025 - 43rd Annual J.P. Morgan Healthcare Conference
- 01.13.2025 - ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
- 01.13.2025 - ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
Recent Filings
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in November:
- Guggenheim’s Inaugural Healthcare Innovation Conference– Participating in a fireside chat on Monday, November 11, 2024, at 10:30 a.m. ET
- Jefferies London Healthcare Conference– Participating in a fireside chat on Thursday, November 21, 2024, at 12:00 p.m. GMT
Live webcasts of the discussions will be available through the investor section of the company’s website atwww.oricpharma.com. Replays of the webcasts will be available for 90 days following the events.
About ORIC Pharmaceuticals, Inc.ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives byOvercoming Resistance In Cancer.ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Beyond these three product candidates, ORIC®is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go towww.oricpharma.com, and follow us onXorLinkedIn.
Contact:Dominic Piscitelli, Chief Financial Officerdominic.piscitelli@oricpharma.cominfo@oricpharma.com
